PDCD1 and neoplasm: Consistent with this, implanted LLC tumours, which are poorly immunogenic “cold” tumours resistant to anti-PD-1 therapy, showed higher expression of BTNL2 compared to PD-L1, and antibody-mediated BTNL2 inhibition yielded a significant therapeutic response (Fig. 1a, Fig. 5; Supplementary Fig. 2c)71.